Systematic Financial Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-165
Closed -$18K 540
2019
Q3
$18K Sell
165
-9,130
-98% -$1.02M ﹤0.01% 523
2019
Q2
$1.03M Sell
9,295
-1,770
-16% -$208K 0.04% 265
2019
Q1
$1.44M Sell
11,065
-13,725
-55% -$1.67M 0.05% 275
2018
Q4
$2.87M Buy
24,790
+5,003
+25% +$559K 0.09% 235
2018
Q3
$2.12M Buy
+19,787
New +$1.98M 0.05% 284
2018
Q1
Sell
-18,235
Closed -$1.54M 659
2017
Q4
$1.54M Sell
18,235
-757
-4% -$64.4K 0.03% 368
2017
Q3
$1.63M Sell
18,992
-1,417
-7% -$116K 0.03% 354
2017
Q2
$1.68M Sell
20,409
-1,260
-6% -$103K 0.03% 458
2017
Q1
$1.82M Sell
21,669
-34,495
-61% -$2.76M 0.03% 386
2016
Q4
$4.13M Buy
+56,164
New +$4.18M 0.07% 296
2015
Q2
Sell
-231,961
Closed -$16.9M 710
2015
Q1
$16.9M Sell
231,961
-13,912
-6% -$990K 0.13% 162
2014
Q4
$17M Buy
245,873
+88,908
+57% +$6M 0.13% 165
2014
Q3
$10.2M Buy
+156,965
New +$9.94M 0.07% 273
2013
Q4
Sell
-582,296
Closed -$29.3M 671
2013
Q3
$29.3M Buy
582,296
+198,375
+52% +$10.4M 0.23% 112
2013
Q2
$18.9M Buy
+383,921
New +$20.9M 0.16% 144

Other funds holding LLY

Systematic Financial Management's LLY Position: Q4 2019 in Review

Systematic Financial Management sold out of Eli Lilly (LLY) in Q4 2019, closing a stake of 165 shares — an estimated $18K sold.

Systematic Financial Management first reported a position in LLY in Q2 2013 and held it in 15 quarters. The position peaked at $29.3M in Q3 2013. 1,672 funds tracked by Wall St. Rank hold LLY as of Q4 2019.

  • Systematic Financial Management reported no remaining Eli Lilly position as of Q4 2019 after selling out during the quarter.
  • Systematic Financial Management sold 165 Eli Lilly shares in Q4 2019, an estimated $18K.
  • Systematic Financial Management first reported a position in Eli Lilly in Q2 2013 and held it in 15 quarters.
  • Systematic Financial Management's Eli Lilly position peaked at $29.3M in Q3 2013.
  • 1,672 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2019.

Based on Systematic Financial Management's 13F filing for Q4 2019, filed 14 Feb 2020.